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Endothelin participates in a variety of conditions that cause pain.
Local injection of ET-1 produces pain which is independent of its
vasoactive properties. Pain due to inﬂammation, nerve injury and
cancer has been studied extensively. Most of the studies indicate that
ETA receptor antagonists decrease nociception; and some studies
indicate that ETB receptor stimulation may be antinociceptive; while
others indicate that ETB receptor antagonism may be anti-
nociceptive. However, the idea of ETB receptor stimulation having
antinociceptive effect is gaining ground. It was demonstrated that
methylation of ETB receptors which results in transcription silencing
is present in painful cancerous tissues and not in normal tissues from
the same patients. Preclinical studies with ETA receptor antagonists
demonstrated potential for reducing pain, and some clinical phase II
studies also showed the beneﬁt of using ETA receptor antagonists in
reducing cancer pain. In experiments carried out in mice, with
deletion of ETA receptors selectively in nociceptive sensory neurons,
while preserving expression in non-neuronal cells and the CNS, it
was found that ETA receptors are important in the modulation of
cancer pain and act independent of ETA receptor function in tumor
cells. However, human phase III studies have failed to demonstrate
any beneﬁt in reducing pain of cancer patients. It has been found that
ETA receptor antagonism predominantly mediates its antinociceptive
action through endogenous opiates. Secretion of beta-endorphin
and leu-enkephalin is increased by ETA receptor antagonists. ETA
receptor antagonists potentiate morphine and oxycodone antino-
ciception in rats and mice; and tolerance to opioid agonists was
reversed by treatment with ETA receptor antagonists. Moreover, ETA
receptor antagonists enhanced G-protein coupling to opioid receptors
and restored morphine analgesia in tolerant animals. This creates the
possibility of combination therapies with opioids and ETA receptor
antagonists to manage pain in cancer patients with lower doses of
opiates and reduced probability of tolerance development.
doi:10.1016/j.lfs.2013.12.104
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Endothelin B (ETB) receptor agonist, IRL-1620, has been shown in
previous studies, conducted in our lab, to provide signiﬁcant neuropro-
tection at both 24 h and 1 week following permanent cerebral ischemia.
It is possible that IRL-1620may be neuroprotective due to angiogenesis
and neurogenesis. However, the effect of IRL-1620 on neurovascular
remodeling following cerebral ischemia has not been established. The
present study was conducted to determine the effect of IRL-1620 [Suc-
[Glu9, Ala11, 15]-Endothelin-1 (8–12)] on astrocytes, neurons, and
vascular endothelial cells after the induction of cerebral ischemia. Male
Sprague-Dawley rats undergoing permanent middle cerebral artery
occlusion (MCAO) received three intravenous injections of either
vehicle or IRL-1620 (5 μg/kg) at 2, 4, and 6 h post occlusion. Brain
tissues of animals euthanized at 24 h or 7 days post occlusion were
processed for immunoﬂuorescent labeling of ETB receptors, astrocytes,
neurons, and vascular and neuronal growth factors. At 24 h post
occlusion, IRL-1620 treatment increased ETB receptor expression and
preserved neuronal numbers in the cortex, striatum and subventricular
zone of the ischemic rat brain. IRL-1620 also enhanced the number of
blood vessels labeled with vascular endothelial growth factor (VEGF)
when compared to vehicle treatment. By 1 week following MCAO,
VEGF-positive vessels/30 μm brain slice in the IRL-1620 group num-
bered 11.33 ± 2.13 versus 4.19 ± 0.79 in the vehicle group (P b 0.01).
Additionally, animals receiving IRL-1620 displayed an increased
number of proliferating cells (P b 0.0001) and cells positively staining
for nerve growth factor (P b 0.0001) in the infarcted brain. Results of
the present study indicate that IRL-1620, administered on the day of
infarct, is neuroprotective and enhances neurovascular remodeling
following cerebral ischemia.
doi:10.1016/j.lfs.2013.12.105
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Exposure to excessive white light induces retinal degeneration or
exacerbates the rate of photoreceptor apoptosis in several retinal diseases.
In this work we analyzed whether the endothelinergic antagonist
Clazosentan (ETRA) could modify the course of light-induced degener-
ation.We also investigated the possible role of ETA in the transmission of
visual stimuli. Male Balb-c mice (5–7 weeks old) were exposed to
phototoxic stimuli (1500 lx) for 2 days and 4 days, or exposed to non-
phototoxic stimuli (0.3 lx at 2 Hz) for 60min (n= 3 per group). During
the exposure period, animals received saline solution or clazosentan
(10 mg/kg/day). 4 days exposed animals were allowed to recover under
standard illumination for another 6 days. Mice were then anesthetized;
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